Vaccine | Efficacy (incidence HZ) | Systemic side effects that prevented normal everyday activities (vaccine versus placebo) | Follow-up | Comment |
ZVL (single dose) | Population ≥60 years of age[1]: 51% reduction in risk of HZ compared with placebo (95% CI 44.2-57.6%; 11.12 versus 5.42 per 1000 person-years) | <1% reported in post-hoc analysis[5] | 3.1 years | Vaccine efficacy was significantly greater in individuals aged 60 to 69 years compared with those ≥70 years (63.9 versus 37.6%). Protection against postherpetic neuralgia was 67%[1]. Observational studies found the protection from ZVL wanes significantly after 5 to 8 years (from approximately 50% to 20 to 30% for those ≥60 years of age)[6-8]. Protection against postherpetic neuralgia was maintained significantly longer. |
Population 50 to 59 years of age[2]: 70% reduction in risk of HZ compared with placebo (95% CI 54.1-80.6%; 6.57 versus 1.99 per 1000 person-years) | 1.3 years | |||
RZV (2 doses separated by 2 months) | Population ≥70 years of age[3]: 89% reduction in risk of HZ compared with placebo (95% CI 84.2-93.7%; 9.2 versus 0.9 per 1000 person-years) | 6 versus 2% | 3.7 years | Myalgia was the most common systemic reaction. Protection against postherpetic neuralgia in patients ≥70 years of age was 89%. |
Population ≥50 years of age[4]: 96.2% reduction in risk of HZ compared with placebo (95% CI 92.7-98.3%; 9.1 versus 0.3 per 1000 person-years) | 11.4 versus 2.4% | 3.2 years |
Do you want to add Medilib to your home screen?